PetIQ, Inc. (NASDAQ:PETQ – Get Rating) – Jefferies Financial Group issued their Q3 2022 earnings per share estimates for PetIQ in a report issued on Wednesday, September 21st. Jefferies Financial Group analyst C. Grady anticipates that the company will earn ($0.12) per share for the quarter. The consensus estimate for PetIQ's current full-year earnings is $0.80 per share. Jefferies Financial Group also issued estimates for PetIQ's Q4 2022 earnings at ($0.16) EPS, FY2022 earnings at $0.62 EPS, Q1 2023 earnings at $0.49 EPS, Q2 2023 earnings at $0.40 EPS, Q3 2023 earnings at ($0.02) EPS, Q4 2023 earnings at ($0.03) EPS and FY2023 earnings at $0.86 EPS.

Separately, Raymond James lowered their price objective on PetIQ from $29.00 to $21.00 in a research report on Wednesday, August 10th.

PetIQ Trading Down 1.1 %

PetIQ (NASDAQ:PETQ – Get Rating) last issued its quarterly earnings data on Tuesday, August 9th. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.24 by $0.18. PetIQ had a positive return on equity of 9.27% and a negative net margin of 1.53%. The company had revenue of $252.01 million for the quarter, compared to the consensus estimate of $259.28 million.

Institutional Investors Weigh In On PetIQ

Large investors have recently added to or reduced their stakes in the company. Byrne Asset Management LLC purchased a new stake in PetIQ during the fourth quarter valued at about $28,000. Captrust Financial Advisors grew its stake in shares of PetIQ by 1,149.6% during the second quarter. Captrust Financial Advisors now owns 1,562 shares of the company's stock valued at $26,000 after buying an additional 1,437 shares during the last quarter. Eagle Bay Advisors LLC grew its stake in shares of PetIQ by 142.9% during the second quarter. Eagle Bay Advisors LLC now owns 1,683 shares of the company's stock valued at $28,000 after buying an additional 990 shares during the last quarter. Amalgamated Bank bought a new position in shares of PetIQ during the first quarter valued at about $107,000. Finally, BNP Paribas Arbitrage SA grew its stake in shares of PetIQ by 20.2% during the fourth quarter. BNP Paribas Arbitrage SA now owns 5,825 shares of the company's stock valued at $132,000 after buying an additional 978 shares during the last quarter.

PetIQ Company Profile

(Get Rating)

PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications.

Featured Stories

• Get a free copy of the StockNews.com research report on PetIQ (PETQ)
• Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
• MarketBeat: Week in Review 9/19 – 9/23
• Why Does Tesla Stock Remain Resilient?
• Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
• 2 Semiconductor Stocks To Watch For Reversals

Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.